# GO_molecular_function_0095

[All questions and paired results](../README.md) · [Method](../METHOD.md) · [Source credits](../THIRD_PARTY_NOTICES.md)

**Task:** `GO_molecular_function`  
**Author expected answer:** **D** — nucleotide binding

| Reviewer | Expected-answer support | Reasoning / lookup | Validity |
|---|---|---|---|
| GPT-6 Luna | supported | lookup-dependent | valid_review |
| Qwen3.8-Flash-Next-NVFP4 | supported | reasoning-supported | valid_review |

**Paired comparison:** key agree; reasoning differ. Agreement is not proof of correctness. These are separate AI judgments, with no forced consensus or changed key.

## Complete original question

```text
[Protein Sequence]
MQAIISTAPGQAALVHDRPLPTIRDGYLLVKTKAVALNPTDWKHIEVTQKPGILFGCDYAGIVEQVGPGVQSGFQPGDRVAGFVHGGNSKEPQDGAFAEYIVAKADLQIHIPEHMSFEEAATLGVGITAVGQGLYQTLSLPFPSPSSIHEDGAEKPANPATQPILIYGASTASGVLGIQFAKLSGFAPLAVCSPDHFDLAERLGAVAVFDYADGEDAVEEIQDYVRGMGQPLLKAWDTISIPSSARFCGDALSSGNGPQYASLLSMTCPRPDVTSTTTMAYTVFGEDWGMGTAHFPASGVDAELGRRWWALVQQLLNEGRIQTHRIIAGEGGLDGVLGGLQQLRDSQVRGGKLVFRV

[Multiple Choices]
A. endopeptidase inhibitor activity
B. 2-oxoglutarate-dependent dioxygenase activity
C. RNA polymerase II general transcription initiation factor activity
D. nucleotide binding
```

<details>
<summary>Original system instructions, verbatim</summary>

```text
You are an excellent scientist. Analyze the provided protein-related task carefully and choose the correct answer from the multiple-choice options.

The current task is about Gene Ontology (GO) Molecular Function Prediction, which is to predict the fundamental activity of a protein at the molecular level, as defined by the Gene Ontology (GO) 'Molecular Function' branch. This describes the elemental tasks a protein performs, such as catalysis, transport, or binding to specific molecules. Based on the protein's amino acid sequence, you are to select the option that best describes its primary molecular function.. The inputs provided by the user for this task include:

* Protein Sequence: The amino acid sequence of the protein.
* Multiple Choices: Candidate answers for the protein-related question.

Please think step-by-step about this problem:
1. Analyze the protein sequence carefully.
2. Consider the biological context and function.
3. Evaluate each multiple-choice option.
4. Provide your reasoning process.
5. Finally, give your answer.

Provide your response in the following format:
1. reasoning: [Your detailed reasoning here]
2. answer: Your final answer, which should be "A", "B", "C" or "D".
```

</details>

## GPT-6 Luna

**Saved status:** `valid_review`.

### Expected-answer support: supported

> A historical UniProt record for the exact sequence annotates nucleotide binding (GO:0000166), with evidence code IEA:UniProtKB-KW. This supports D as a database annotation, though it is not experimental evidence of binding. The same record describes the protein as a trans-enoyl reductase.

Citations as saved: [H3](#evidence-h3), [H4](#evidence-h4).

### Reasoning versus lookup: lookup-dependent

**Discriminating biological argument**

> Nucleotide-cofactor use is plausible for an oxidoreductase and makes D more plausible than the unrelated inhibitor, dioxygenase, and transcription-factor choices. But that broad tendency does not establish that this particular protein binds a nucleotide.


**Missing item-specific fact**

> The protein-specific functional annotation or evidence that this trans-enoyl reductase binds a nucleotide cofactor is absent from the input.


**Reason**

> The sequence alone does not provide a sufficiently decisive basis for assigning nucleotide binding; identifying the specific enzyme family and its cofactor or consulting its annotation is needed.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[]
```

> Among the listed choices, nucleotide binding is supported by the matched-sequence annotation; the supplied evidence does not support another listed option.


### Important caveats

- The nucleotide-binding annotation is computationally assigned (IEA:UniProtKB-KW), not direct experimental evidence.
- The protein’s described enzymatic function, trans-enoyl reductase, is not itself one of the answer choices.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "Nucleotide-cofactor use is plausible for an oxidoreductase and makes D more plausible than the unrelated inhibitor, dioxygenase, and transcription-factor choices. But that broad tendency does not establish that this particular protein binds a nucleotide.",
    "judgment": "lookup_or_memorization_dependent",
    "missing_item_specific_fact": "The protein-specific functional annotation or evidence that this trans-enoyl reductase binds a nucleotide cofactor is absent from the input.",
    "reason": "The sequence alone does not provide a sufficiently decisive basis for assigning nucleotide binding; identifying the specific enzyme family and its cofactor or consulting its annotation is needed."
  },
  "case_id": "GO_molecular_function_0095",
  "expected_answer_check": {
    "evidence_ids": [
      "H3",
      "H4"
    ],
    "judgment": "supported",
    "reason": "A historical UniProt record for the exact sequence annotates nucleotide binding (GO:0000166), with evidence code IEA:UniProtKB-KW. This supports D as a database annotation, though it is not experimental evidence of binding. The same record describes the protein as a trans-enoyl reductase."
  },
  "important_caveats": [
    "The nucleotide-binding annotation is computationally assigned (IEA:UniProtKB-KW), not direct experimental evidence.",
    "The protein’s described enzymatic function, trans-enoyl reductase, is not itself one of the answer choices."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "Among the listed choices, nucleotide binding is supported by the matched-sequence annotation; the supplied evidence does not support another listed option."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text
{
  "case_id": "GO_molecular_function_0095",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "A historical UniProt record for the exact sequence annotates nucleotide binding (GO:0000166), with evidence code IEA:UniProtKB-KW. This supports D as a database annotation, though it is not experimental evidence of binding. The same record describes the protein as a trans-enoyl reductase.",
    "evidence_ids": ["H3", "H4"]
  },
  "answerability_check": {
    "judgment": "lookup_or_memorization_dependent",
    "discriminating_biological_argument": "Nucleotide-cofactor use is plausible for an oxidoreductase and makes D more plausible than the unrelated inhibitor, dioxygenase, and transcription-factor choices. But that broad tendency does not establish that this particular protein binds a nucleotide.",
    "missing_item_specific_fact": "The protein-specific functional annotation or evidence that this trans-enoyl reductase binds a nucleotide cofactor is absent from the input.",
    "reason": "The sequence alone does not provide a sufficiently decisive basis for assigning nucleotide binding; identifying the specific enzyme family and its cofactor or consulting its annotation is needed."
  },
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "Among the listed choices, nucleotide binding is supported by the matched-sequence annotation; the supplied evidence does not support another listed option."
  },
  "important_caveats": [
    "The nucleotide-binding annotation is computationally assigned (IEA:UniProtKB-KW), not direct experimental evidence.",
    "The protein’s described enzymatic function, trans-enoyl reductase, is not itself one of the answer choices."
  ]
}
```

</details>

## Qwen3.8-Flash-Next-NVFP4

**Saved status:** `valid_review`.

### Expected-answer support: supported

> The UniProt entry P0DXV9 carries GO:0000166 (nucleotide binding) as an IEA:UniProtKB-KW annotation (evidence H4). This is the only one of the four option terms present in the protein's GO annotations. The other three options (endopeptidase inhibitor, 2-oxoglutarate-dependent dioxygenase, RNA Pol II transcription factor) have no annotation support. However, the annotation is IEA (inferred from electronic keyword), not experimental, and the protein's true primary molecular function is trans-enoyl reductase / oxidoreductase activity (GO:0016651, also IEA:InterPro), which is not among the choices. Nucleotide binding is a secondary cofactor-binding attribute, not the primary catalytic function.

Citations as saved: [H4](#evidence-h4), [H5](#evidence-h5), [C6](#evidence-c6).

### Reasoning versus lookup: reasoning-supported

**Discriminating biological argument**

> The sequence contains motifs consistent with an NAD(P)H-binding reductase domain (e.g., GxGxxG-like patterns such as 'GEWGMG' and 'GASTASG', and overall domain architecture typical of enoyl-reductase / short-chain dehydrogenase domains found in PKS clusters). A reductase binds a nucleotide cofactor (NAD(P)H), making 'nucleotide binding' the only option consistent with a reductase. Options A (endopeptidase inhibitor), B (2-oxoglutarate-dependent dioxygenase, requiring a His/His/Asp triad and specific substrate-binding pocket), and C (RNA Pol II general transcription factor, requiring protein-protein interaction domains like TFIIB/TFIID motifs) are all inconsistent with the observed sequence features. This elimination-based reasoning provides meaningful grounds to select D.


**Missing item-specific fact**

> None strictly required; however, the question's framing as 'primary molecular function' is misleading because the true primary function is oxidoreductase (enoyl reductase) activity, not nucleotide binding. The answer relies on the fact that oxidoreductase is not among the options, forcing selection of the broad secondary annotation.


**Reason**

> General biological knowledge (reductases bind NAD(P)H; dioxygenases require 2-oxoglutarate-binding motifs; transcription factors have distinct domain architectures) provides a concrete path to eliminate A, B, C and select D. The reasoning is somewhat indirect because 'nucleotide binding' is a broad secondary annotation rather than the true primary catalytic function, but the elimination logic is defensible from sequence features alone.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[]
```

> Options A, B, and C are clearly inconsistent with any reductase-like protein. Among the four choices, only D has any annotation support and any biological plausibility. The ambiguity lies not between the options but in the question stem's use of 'primary molecular function' when the true primary function (oxidoreductase/enoyl reductase) is not offered, making D the 'best available' rather than the 'primary' function.


### Important caveats

- The GO:0000166 annotation is IEA:UniProtKB-KW (keyword-inferred), not experimentally validated. It reflects a broad cofactor-binding attribute, not the protein's defining catalytic activity.
- The protein's primary molecular function is trans-enoyl reductase (oxidoreductase, GO:0016651, IEA:InterPro). The question stem asks for 'primary molecular function' but the correct answer is a secondary binding annotation, creating a mismatch between the question framing and the answer.
- The sequence match to P0DXV9 is confirmed (SHA-256 match, 357 aa, sequence version 1). The entry was first released 2025-02-05.
- All evidence codes for the relevant GO annotations are IEA (computational inference), not experimental (no IDA, IMP, IPI, etc.).

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "The sequence contains motifs consistent with an NAD(P)H-binding reductase domain (e.g., GxGxxG-like patterns such as 'GEWGMG' and 'GASTASG', and overall domain architecture typical of enoyl-reductase / short-chain dehydrogenase domains found in PKS clusters). A reductase binds a nucleotide cofactor (NAD(P)H), making 'nucleotide binding' the only option consistent with a reductase. Options A (endopeptidase inhibitor), B (2-oxoglutarate-dependent dioxygenase, requiring a His/His/Asp triad and specific substrate-binding pocket), and C (RNA Pol II general transcription factor, requiring protein-protein interaction domains like TFIIB/TFIID motifs) are all inconsistent with the observed sequence features. This elimination-based reasoning provides meaningful grounds to select D.",
    "judgment": "reasoning_supported",
    "missing_item_specific_fact": "None strictly required; however, the question's framing as 'primary molecular function' is misleading because the true primary function is oxidoreductase (enoyl reductase) activity, not nucleotide binding. The answer relies on the fact that oxidoreductase is not among the options, forcing selection of the broad secondary annotation.",
    "reason": "General biological knowledge (reductases bind NAD(P)H; dioxygenases require 2-oxoglutarate-binding motifs; transcription factors have distinct domain architectures) provides a concrete path to eliminate A, B, C and select D. The reasoning is somewhat indirect because 'nucleotide binding' is a broad secondary annotation rather than the true primary catalytic function, but the elimination logic is defensible from sequence features alone."
  },
  "case_id": "GO_molecular_function_0095",
  "expected_answer_check": {
    "evidence_ids": [
      "H4",
      "H5",
      "C6"
    ],
    "judgment": "supported",
    "reason": "The UniProt entry P0DXV9 carries GO:0000166 (nucleotide binding) as an IEA:UniProtKB-KW annotation (evidence H4). This is the only one of the four option terms present in the protein's GO annotations. The other three options (endopeptidase inhibitor, 2-oxoglutarate-dependent dioxygenase, RNA Pol II transcription factor) have no annotation support. However, the annotation is IEA (inferred from electronic keyword), not experimental, and the protein's true primary molecular function is trans-enoyl reductase / oxidoreductase activity (GO:0016651, also IEA:InterPro), which is not among the choices. Nucleotide binding is a secondary cofactor-binding attribute, not the primary catalytic function."
  },
  "important_caveats": [
    "The GO:0000166 annotation is IEA:UniProtKB-KW (keyword-inferred), not experimentally validated. It reflects a broad cofactor-binding attribute, not the protein's defining catalytic activity.",
    "The protein's primary molecular function is trans-enoyl reductase (oxidoreductase, GO:0016651, IEA:InterPro). The question stem asks for 'primary molecular function' but the correct answer is a secondary binding annotation, creating a mismatch between the question framing and the answer.",
    "The sequence match to P0DXV9 is confirmed (SHA-256 match, 357 aa, sequence version 1). The entry was first released 2025-02-05.",
    "All evidence codes for the relevant GO annotations are IEA (computational inference), not experimental (no IDA, IMP, IPI, etc.)."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "Options A, B, and C are clearly inconsistent with any reductase-like protein. Among the four choices, only D has any annotation support and any biological plausibility. The ambiguity lies not between the options but in the question stem's use of 'primary molecular function' when the true primary function (oxidoreductase/enoyl reductase) is not offered, making D the 'best available' rather than the 'primary' function."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text


{
  "case_id": "GO_molecular_function_0095",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "The UniProt entry P0DXV9 carries GO:0000166 (nucleotide binding) as an IEA:UniProtKB-KW annotation (evidence H4). This is the only one of the four option terms present in the protein's GO annotations. The other three options (endopeptidase inhibitor, 2-oxoglutarate-dependent dioxygenase, RNA Pol II transcription factor) have no annotation support. However, the annotation is IEA (inferred from electronic keyword), not experimental, and the protein's true primary molecular function is trans-enoyl reductase / oxidoreductase activity (GO:0016651, also IEA:InterPro), which is not among the choices. Nucleotide binding is a secondary cofactor-binding attribute, not the primary catalytic function.",
    "evidence_ids": ["H4", "H5", "C6"]
  },
  "answerability_check": {
    "judgment": "reasoning_supported",
    "discriminating_biological_argument": "The sequence contains motifs consistent with an NAD(P)H-binding reductase domain (e.g., GxGxxG-like patterns such as 'GEWGMG' and 'GASTASG', and overall domain architecture typical of enoyl-reductase / short-chain dehydrogenase domains found in PKS clusters). A reductase binds a nucleotide cofactor (NAD(P)H), making 'nucleotide binding' the only option consistent with a reductase. Options A (endopeptidase inhibitor), B (2-oxoglutarate-dependent dioxygenase, requiring a His/His/Asp triad and specific substrate-binding pocket), and C (RNA Pol II general transcription factor, requiring protein-protein interaction domains like TFIIB/TFIID motifs) are all inconsistent with the observed sequence features. This elimination-based reasoning provides meaningful grounds to select D.",
    "missing_item_specific_fact": "None strictly required; however, the question's framing as 'primary molecular function' is misleading because the true primary function is oxidoreductase (enoyl reductase) activity, not nucleotide binding. The answer relies on the fact that oxidoreductase is not among the options, forcing selection of the broad secondary annotation.",
    "reason": "General biological knowledge (reductases bind NAD(P)H; dioxygenases require 2-oxoglutarate-binding motifs; transcription factors have distinct domain architectures) provides a concrete path to eliminate A, B, C and select D. The reasoning is somewhat indirect because 'nucleotide binding' is a broad secondary annotation rather than the true primary catalytic function, but the elimination logic is defensible from sequence features alone."
  },
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "Options A, B, and C are clearly inconsistent with any reductase-like protein. Among the four choices, only D has any annotation support and any biological plausibility. The ambiguity lies not between the options but in the question stem's use of 'primary molecular function' when the true primary function (oxidoreductase/enoyl reductase) is not offered, making D the 'best available' rather than the 'primary' function."
  },
  "important_caveats": [
    "The GO:0000166 annotation is IEA:UniProtKB-KW (keyword-inferred), not experimentally validated. It reflects a broad cofactor-binding attribute, not the protein's defining catalytic activity.",
    "The protein's primary molecular function is trans-enoyl reductase (oxidoreductase, GO:0016651, IEA:InterPro). The question stem asks for 'primary molecular function' but the correct answer is a secondary binding annotation, creating a mismatch between the question framing and the answer.",
    "The sequence match to P0DXV9 is confirmed (SHA-256 match, 357 aa, sequence version 1). The entry was first released 2025-02-05.",
    "All evidence codes for the relevant GO annotations are IEA (computational inference), not experimental (no IDA, IMP, IPI, etc.)."
  ]
}
```

</details>

## Existing project source checks of Luna’s review

The notes below were prepared for specific claims in the Luna review. They are not independent validation of Qwen’s claims, expert adjudication, or replacement verdicts.

## Project source-check notes

These project-authored, AI-assisted checks assess specific source claims. They are not expert adjudication and do not replace Luna’s saved review or the author key.

No additional case-specific project note was recorded. Citation membership checks do not establish that every scientific argument is correct.

## Reviewer-only source evidence

**Both reviewers received this source evidence separately from the original question. It was not available to the original evaluated model.** Source support and reasoning from the original sequence/choices are distinct assessments.

**Accession:** `P0DXV9` (recovered from dataset image-path metadata, not original question text).  
**Sequence applicability:** historical matched; current matched.  
**Historical cutoff:** 2026-05-07; archived entry version 4. Exact author snapshot unknown.

- All evidence and source identity in this section are reviewer-only and were absent from the evaluated model input.
- UniProt annotations may be experimental, computational, or transferred by similarity; evidence codes and qualifiers are retained.
- The 2026-05-07 cutoff approximates the pinned repository date; the author data-construction date and exact source snapshot remain unknown.
- Selected source fields are excerpts; missing annotation is not evidence of falsehood. Primary papers were not comprehensively retrieved or independently validated.
- Ontology names and EXACT synonyms match options mechanically; no answer-support judgment is made.
- Only is_a and part_of edges are used in supplied graph paths; all qualifiers and obsolete/replaced_by tags remain in literal source blocks.
- The ontology is newer than the benchmark repository commit; the exact author ontology snapshot is unknown.
- No matching term or path does not establish that an option is false.

### Evidence C6

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/P0DXV9.json)  
**Locator:** `/uniProtKBCrossReferences/2`  
**Scope:** current snapshot; actual author source snapshot unknown.  
**Sequence comparison:** matched.  
**Retrieved:** 2026-11-02T04:29:49.517632+00:00.  

```json
{"database":"GO","id":"GO:0016651","properties":[{"key":"GoTerm","value":"F:oxidoreductase activity, acting on NAD(P)H"},{"key":"GoEvidenceType","value":"IEA:InterPro"}]}
```

Source SHA-256: `0ea3f01218a5d44f3983e214db9b5571f37b981454f4a8fcafcef626a639e914`.

### Evidence H3

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/P0DXV9?format=txt&versions=4)  
**Locator:** `lines 22-36`  
**Scope:** record released no later than 2026-05-07; actual author source snapshot unknown.  
**Sequence comparison:** matched.  
**Entry / sequence version:** 4 / 1.  
**Retrieved:** 2026-11-02T04:29:51.221408+00:00.  

```text
CC   -!- FUNCTION: Trans-enoyl reductase; part of the gene cluster that mediates
CC       the biosynthesis of the tetrahydropyranyl antifungal agent restricticin
CC       that acts as an inhibitor of CYP51 and blocks the ergosterol
CC       biosynthesis (PubMed:39105744). The highly reducing polyketide synthase
CC       resH, the short chain dehydrogenase resG, the cyclase resF, the FAD-
CC       dependent monooxygenase resA and the enoylreductase resD are required
CC       to generate the first stable intermediate desmethylrestrictinol. ResH
CC       with resD biosynthesize the first polyketide chain intermediate that is
CC       reduced by resG, followed by epoxidation by resA before 6-endo
CC       cyclization via epoxide opening by resF leads to desmethylrestrictinol.
CC       The methyltransferase resE then catalyzes the C4 O-methylation of
CC       desmethylrestrictinol to produce restrictinol, and the nonribosomal
CC       peptide synthetase resC catalyzes the C3 esterification of restrictinol
CC       with glycine that leads to restricticin (By similarity).
CC       {ECO:0000250|UniProtKB:A0A0L1JEX1, ECO:0000269|PubMed:39105744}.
```

Source SHA-256: `50948681abaa65d91ada1f1b7abe16915d33f113843973d2c3d87f65be73d5b0`.

### Evidence H4

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/P0DXV9?format=txt&versions=4)  
**Locator:** `lines 45-45`  
**Scope:** record released no later than 2026-05-07; actual author source snapshot unknown.  
**Sequence comparison:** matched.  
**Entry / sequence version:** 4 / 1.  
**Retrieved:** 2026-11-02T04:29:51.221408+00:00.  

```text
DR   GO; GO:0000166; F:nucleotide binding; IEA:UniProtKB-KW.
```

Source SHA-256: `50948681abaa65d91ada1f1b7abe16915d33f113843973d2c3d87f65be73d5b0`.

### Evidence H5

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/P0DXV9?format=txt&versions=4)  
**Locator:** `lines 46-46`  
**Scope:** record released no later than 2026-05-07; actual author source snapshot unknown.  
**Sequence comparison:** matched.  
**Entry / sequence version:** 4 / 1.  
**Retrieved:** 2026-11-02T04:29:51.221408+00:00.  

```text
DR   GO; GO:0016651; F:oxidoreductase activity, acting on NAD(P)H; IEA:InterPro.
```

Source SHA-256: `50948681abaa65d91ada1f1b7abe16915d33f113843973d2c3d87f65be73d5b0`.

---

Original question/key: [pinned source](https://github.com/Rongdingyi/LiveProteinBench/blob/8b9710932511f816651fc1a7e8a1bc85c3c77767/dataset/QA/GO_molecular_function.json), zero-based source row 95. © 2026 LiveProteinBench contributors; [CC BY 4.0](https://huggingface.co/datasets/LiveProteinBench/LiveProteinBench/blob/8428f64e33d53330f7745376d9c45de2d2c37eaf/LICENSE). UniProt and Gene Ontology credits are retained in [source notices](../THIRD_PARTY_NOTICES.md).
